The Use of Aspirin Increases the Risk of Major Adverse Cardiac and Cerebrovascular Events in Hypertensive Patients with Obstructive Sleep Apnea for the Primary Prevention of Cardiovascular Disease: A Real-World Cohort Study
(1) Background: Hypertensive patients with obstructive sleep apnea (OSA) are at high risk for cardiovascular diseases (CVDs), and the utility of aspirin for primary cardiovascular prevention in this population remains uncertain. (2) Methods: In this retrospective cohort study using data from the <...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-11-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/11/23/7066 |
| _version_ | 1797462921228320768 |
|---|---|
| author | Nanfang Li Wen Wen Xintian Cai Qing Zhu Junli Hu Mulalibieke Heizhati Yujuan Yuan Lin Gan Yujie Dang Wenbo Yang Jing Hong Xiangyang Zhang |
| author_facet | Nanfang Li Wen Wen Xintian Cai Qing Zhu Junli Hu Mulalibieke Heizhati Yujuan Yuan Lin Gan Yujie Dang Wenbo Yang Jing Hong Xiangyang Zhang |
| author_sort | Nanfang Li |
| collection | DOAJ |
| description | (1) Background: Hypertensive patients with obstructive sleep apnea (OSA) are at high risk for cardiovascular diseases (CVDs), and the utility of aspirin for primary cardiovascular prevention in this population remains uncertain. (2) Methods: In this retrospective cohort study using data from the <i>Urumchi Hypertension Database</i> (UHDATA), hypertensive patients older than 18 years old with a first-time diagnosis of OSA were divided into three groups depending on aspirin history. Major adverse cardiac and cerebrovascular events (MACCE) were the primary outcome. Secondary outcomes included MACCE components, ischemic events, cardiac events, cerebrovascular events, and gastrointestinal bleeding risk. The inverse probability of treatment weighting (IPTW) method was used to balance the confounding factors among the groups, and the Cox proportional hazards model was used to calculate the hazard ratio (HR) and 95% confidence interval (CI). (3) Results: In persistent aspirin users, the risk of MACCE events (HR 2.11, 95%CI 1.23–3.63), ischemic events (HR 2.58, 95%CI 1.42–4.69), cerebrovascular events (HR 2.55, 95%CI 1.44–4.51), and non-fatal cerebral infarction (HR 3.14, 95%CI 1.69–5.84) was significantly elevated. (4) Conclusions: Continuous aspirin use increases the incidence of cardiovascular adverse events in hypertensive patients with OSA receiving aspirin for primary prevention of cardiovascular disease. |
| first_indexed | 2024-03-09T17:43:22Z |
| format | Article |
| id | doaj.art-37ffb58360234e8fa230293df5613b58 |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-09T17:43:22Z |
| publishDate | 2022-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-37ffb58360234e8fa230293df5613b582023-11-24T11:22:18ZengMDPI AGJournal of Clinical Medicine2077-03832022-11-011123706610.3390/jcm11237066The Use of Aspirin Increases the Risk of Major Adverse Cardiac and Cerebrovascular Events in Hypertensive Patients with Obstructive Sleep Apnea for the Primary Prevention of Cardiovascular Disease: A Real-World Cohort StudyNanfang Li0Wen Wen1Xintian Cai2Qing Zhu3Junli Hu4Mulalibieke Heizhati5Yujuan Yuan6Lin Gan7Yujie Dang8Wenbo Yang9Jing Hong10Xiangyang Zhang11Hypertension Center of People’s Hospital of Xinjiang Uygur Autonomous Region, Xinjiang Hypertension Institute, NHC Key Laboratory of Hypertension Clinical Research, Key Laboratory of Xinjiang Uygur Autonomous Region, Xinjiang Clinical Medical Research Center for Hypertension Diseases, Urumqi 830000, ChinaSchool of Graduate Studies, Xinjiang Medical University, Urumqi 830000, ChinaHypertension Center of People’s Hospital of Xinjiang Uygur Autonomous Region, Xinjiang Hypertension Institute, NHC Key Laboratory of Hypertension Clinical Research, Key Laboratory of Xinjiang Uygur Autonomous Region, Xinjiang Clinical Medical Research Center for Hypertension Diseases, Urumqi 830000, ChinaHypertension Center of People’s Hospital of Xinjiang Uygur Autonomous Region, Xinjiang Hypertension Institute, NHC Key Laboratory of Hypertension Clinical Research, Key Laboratory of Xinjiang Uygur Autonomous Region, Xinjiang Clinical Medical Research Center for Hypertension Diseases, Urumqi 830000, ChinaHypertension Center of People’s Hospital of Xinjiang Uygur Autonomous Region, Xinjiang Hypertension Institute, NHC Key Laboratory of Hypertension Clinical Research, Key Laboratory of Xinjiang Uygur Autonomous Region, Xinjiang Clinical Medical Research Center for Hypertension Diseases, Urumqi 830000, ChinaHypertension Center of People’s Hospital of Xinjiang Uygur Autonomous Region, Xinjiang Hypertension Institute, NHC Key Laboratory of Hypertension Clinical Research, Key Laboratory of Xinjiang Uygur Autonomous Region, Xinjiang Clinical Medical Research Center for Hypertension Diseases, Urumqi 830000, ChinaHypertension Center of People’s Hospital of Xinjiang Uygur Autonomous Region, Xinjiang Hypertension Institute, NHC Key Laboratory of Hypertension Clinical Research, Key Laboratory of Xinjiang Uygur Autonomous Region, Xinjiang Clinical Medical Research Center for Hypertension Diseases, Urumqi 830000, ChinaHypertension Center of People’s Hospital of Xinjiang Uygur Autonomous Region, Xinjiang Hypertension Institute, NHC Key Laboratory of Hypertension Clinical Research, Key Laboratory of Xinjiang Uygur Autonomous Region, Xinjiang Clinical Medical Research Center for Hypertension Diseases, Urumqi 830000, ChinaHypertension Center of People’s Hospital of Xinjiang Uygur Autonomous Region, Xinjiang Hypertension Institute, NHC Key Laboratory of Hypertension Clinical Research, Key Laboratory of Xinjiang Uygur Autonomous Region, Xinjiang Clinical Medical Research Center for Hypertension Diseases, Urumqi 830000, ChinaHypertension Center of People’s Hospital of Xinjiang Uygur Autonomous Region, Xinjiang Hypertension Institute, NHC Key Laboratory of Hypertension Clinical Research, Key Laboratory of Xinjiang Uygur Autonomous Region, Xinjiang Clinical Medical Research Center for Hypertension Diseases, Urumqi 830000, ChinaHypertension Center of People’s Hospital of Xinjiang Uygur Autonomous Region, Xinjiang Hypertension Institute, NHC Key Laboratory of Hypertension Clinical Research, Key Laboratory of Xinjiang Uygur Autonomous Region, Xinjiang Clinical Medical Research Center for Hypertension Diseases, Urumqi 830000, ChinaThe First Affiliated Hospital of Xinjiang Medical University, Urumqi 830000, China(1) Background: Hypertensive patients with obstructive sleep apnea (OSA) are at high risk for cardiovascular diseases (CVDs), and the utility of aspirin for primary cardiovascular prevention in this population remains uncertain. (2) Methods: In this retrospective cohort study using data from the <i>Urumchi Hypertension Database</i> (UHDATA), hypertensive patients older than 18 years old with a first-time diagnosis of OSA were divided into three groups depending on aspirin history. Major adverse cardiac and cerebrovascular events (MACCE) were the primary outcome. Secondary outcomes included MACCE components, ischemic events, cardiac events, cerebrovascular events, and gastrointestinal bleeding risk. The inverse probability of treatment weighting (IPTW) method was used to balance the confounding factors among the groups, and the Cox proportional hazards model was used to calculate the hazard ratio (HR) and 95% confidence interval (CI). (3) Results: In persistent aspirin users, the risk of MACCE events (HR 2.11, 95%CI 1.23–3.63), ischemic events (HR 2.58, 95%CI 1.42–4.69), cerebrovascular events (HR 2.55, 95%CI 1.44–4.51), and non-fatal cerebral infarction (HR 3.14, 95%CI 1.69–5.84) was significantly elevated. (4) Conclusions: Continuous aspirin use increases the incidence of cardiovascular adverse events in hypertensive patients with OSA receiving aspirin for primary prevention of cardiovascular disease.https://www.mdpi.com/2077-0383/11/23/7066obstructive sleep apneahypertensionaspirincardiovascular diseasesprimary preventionreal world study |
| spellingShingle | Nanfang Li Wen Wen Xintian Cai Qing Zhu Junli Hu Mulalibieke Heizhati Yujuan Yuan Lin Gan Yujie Dang Wenbo Yang Jing Hong Xiangyang Zhang The Use of Aspirin Increases the Risk of Major Adverse Cardiac and Cerebrovascular Events in Hypertensive Patients with Obstructive Sleep Apnea for the Primary Prevention of Cardiovascular Disease: A Real-World Cohort Study Journal of Clinical Medicine obstructive sleep apnea hypertension aspirin cardiovascular diseases primary prevention real world study |
| title | The Use of Aspirin Increases the Risk of Major Adverse Cardiac and Cerebrovascular Events in Hypertensive Patients with Obstructive Sleep Apnea for the Primary Prevention of Cardiovascular Disease: A Real-World Cohort Study |
| title_full | The Use of Aspirin Increases the Risk of Major Adverse Cardiac and Cerebrovascular Events in Hypertensive Patients with Obstructive Sleep Apnea for the Primary Prevention of Cardiovascular Disease: A Real-World Cohort Study |
| title_fullStr | The Use of Aspirin Increases the Risk of Major Adverse Cardiac and Cerebrovascular Events in Hypertensive Patients with Obstructive Sleep Apnea for the Primary Prevention of Cardiovascular Disease: A Real-World Cohort Study |
| title_full_unstemmed | The Use of Aspirin Increases the Risk of Major Adverse Cardiac and Cerebrovascular Events in Hypertensive Patients with Obstructive Sleep Apnea for the Primary Prevention of Cardiovascular Disease: A Real-World Cohort Study |
| title_short | The Use of Aspirin Increases the Risk of Major Adverse Cardiac and Cerebrovascular Events in Hypertensive Patients with Obstructive Sleep Apnea for the Primary Prevention of Cardiovascular Disease: A Real-World Cohort Study |
| title_sort | use of aspirin increases the risk of major adverse cardiac and cerebrovascular events in hypertensive patients with obstructive sleep apnea for the primary prevention of cardiovascular disease a real world cohort study |
| topic | obstructive sleep apnea hypertension aspirin cardiovascular diseases primary prevention real world study |
| url | https://www.mdpi.com/2077-0383/11/23/7066 |
| work_keys_str_mv | AT nanfangli theuseofaspirinincreasestheriskofmajoradversecardiacandcerebrovasculareventsinhypertensivepatientswithobstructivesleepapneafortheprimarypreventionofcardiovasculardiseasearealworldcohortstudy AT wenwen theuseofaspirinincreasestheriskofmajoradversecardiacandcerebrovasculareventsinhypertensivepatientswithobstructivesleepapneafortheprimarypreventionofcardiovasculardiseasearealworldcohortstudy AT xintiancai theuseofaspirinincreasestheriskofmajoradversecardiacandcerebrovasculareventsinhypertensivepatientswithobstructivesleepapneafortheprimarypreventionofcardiovasculardiseasearealworldcohortstudy AT qingzhu theuseofaspirinincreasestheriskofmajoradversecardiacandcerebrovasculareventsinhypertensivepatientswithobstructivesleepapneafortheprimarypreventionofcardiovasculardiseasearealworldcohortstudy AT junlihu theuseofaspirinincreasestheriskofmajoradversecardiacandcerebrovasculareventsinhypertensivepatientswithobstructivesleepapneafortheprimarypreventionofcardiovasculardiseasearealworldcohortstudy AT mulalibiekeheizhati theuseofaspirinincreasestheriskofmajoradversecardiacandcerebrovasculareventsinhypertensivepatientswithobstructivesleepapneafortheprimarypreventionofcardiovasculardiseasearealworldcohortstudy AT yujuanyuan theuseofaspirinincreasestheriskofmajoradversecardiacandcerebrovasculareventsinhypertensivepatientswithobstructivesleepapneafortheprimarypreventionofcardiovasculardiseasearealworldcohortstudy AT lingan theuseofaspirinincreasestheriskofmajoradversecardiacandcerebrovasculareventsinhypertensivepatientswithobstructivesleepapneafortheprimarypreventionofcardiovasculardiseasearealworldcohortstudy AT yujiedang theuseofaspirinincreasestheriskofmajoradversecardiacandcerebrovasculareventsinhypertensivepatientswithobstructivesleepapneafortheprimarypreventionofcardiovasculardiseasearealworldcohortstudy AT wenboyang theuseofaspirinincreasestheriskofmajoradversecardiacandcerebrovasculareventsinhypertensivepatientswithobstructivesleepapneafortheprimarypreventionofcardiovasculardiseasearealworldcohortstudy AT jinghong theuseofaspirinincreasestheriskofmajoradversecardiacandcerebrovasculareventsinhypertensivepatientswithobstructivesleepapneafortheprimarypreventionofcardiovasculardiseasearealworldcohortstudy AT xiangyangzhang theuseofaspirinincreasestheriskofmajoradversecardiacandcerebrovasculareventsinhypertensivepatientswithobstructivesleepapneafortheprimarypreventionofcardiovasculardiseasearealworldcohortstudy AT nanfangli useofaspirinincreasestheriskofmajoradversecardiacandcerebrovasculareventsinhypertensivepatientswithobstructivesleepapneafortheprimarypreventionofcardiovasculardiseasearealworldcohortstudy AT wenwen useofaspirinincreasestheriskofmajoradversecardiacandcerebrovasculareventsinhypertensivepatientswithobstructivesleepapneafortheprimarypreventionofcardiovasculardiseasearealworldcohortstudy AT xintiancai useofaspirinincreasestheriskofmajoradversecardiacandcerebrovasculareventsinhypertensivepatientswithobstructivesleepapneafortheprimarypreventionofcardiovasculardiseasearealworldcohortstudy AT qingzhu useofaspirinincreasestheriskofmajoradversecardiacandcerebrovasculareventsinhypertensivepatientswithobstructivesleepapneafortheprimarypreventionofcardiovasculardiseasearealworldcohortstudy AT junlihu useofaspirinincreasestheriskofmajoradversecardiacandcerebrovasculareventsinhypertensivepatientswithobstructivesleepapneafortheprimarypreventionofcardiovasculardiseasearealworldcohortstudy AT mulalibiekeheizhati useofaspirinincreasestheriskofmajoradversecardiacandcerebrovasculareventsinhypertensivepatientswithobstructivesleepapneafortheprimarypreventionofcardiovasculardiseasearealworldcohortstudy AT yujuanyuan useofaspirinincreasestheriskofmajoradversecardiacandcerebrovasculareventsinhypertensivepatientswithobstructivesleepapneafortheprimarypreventionofcardiovasculardiseasearealworldcohortstudy AT lingan useofaspirinincreasestheriskofmajoradversecardiacandcerebrovasculareventsinhypertensivepatientswithobstructivesleepapneafortheprimarypreventionofcardiovasculardiseasearealworldcohortstudy AT yujiedang useofaspirinincreasestheriskofmajoradversecardiacandcerebrovasculareventsinhypertensivepatientswithobstructivesleepapneafortheprimarypreventionofcardiovasculardiseasearealworldcohortstudy AT wenboyang useofaspirinincreasestheriskofmajoradversecardiacandcerebrovasculareventsinhypertensivepatientswithobstructivesleepapneafortheprimarypreventionofcardiovasculardiseasearealworldcohortstudy AT jinghong useofaspirinincreasestheriskofmajoradversecardiacandcerebrovasculareventsinhypertensivepatientswithobstructivesleepapneafortheprimarypreventionofcardiovasculardiseasearealworldcohortstudy AT xiangyangzhang useofaspirinincreasestheriskofmajoradversecardiacandcerebrovasculareventsinhypertensivepatientswithobstructivesleepapneafortheprimarypreventionofcardiovasculardiseasearealworldcohortstudy |